1-(2-hydroxyethyl)-5-ethyl-2-phenyl-1H-pyrrole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 1-(2-hydroxyethyl)-5-ethyl-2-phenyl-1H-pyrrole
• 英文别名: 1-(2-hydroxyethyl)-5-ethyl-2phenyl-1H-pyrrole；2-(2-Ethyl-5-phenyl-1H-pyrrol-1-yl)ethanol；2-(2-ethyl-5-phenylpyrrol-1-yl)ethanol
• 化学式: C₁₄H₁₇NO
• 分子量: 215.295
• InChiKey: ACXLNFCRKYSEPH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  25.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-(2-hydroxyethyl)-5-ethyl-2-phenyl-1H-pyrrole 、 甲基磺酰氯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 以92%的产率得到methyl 2-(5-ethyl-2-phenyl-1H-pyrrol-1-yl)ethane sulfonate
  参考文献：
  名称：

  Novel heterocyclic compounds having hypolipidemic, hypocholesteremic activities process for their preparation and pharmaceutical compositions containing them and their use in medicine

  摘要：

  具有降脂和降胆固醇活性的新型β-芳基-α-取代丙酸。

  公开号：

  US20030236254A1
• 作为产物：
  描述：

  1-苯基己烷-1,4-二酮 、 C.I.酸性橙108 在 三甲基乙酸 、 sodium chloride 作用下， 以 四氢呋喃 、 正庚烷 、 甲苯 为溶剂， 反应 4.0h， 以82%的产率得到1-(2-hydroxyethyl)-5-ethyl-2-phenyl-1H-pyrrole
  参考文献：
  名称：

  Novel heterocyclic compounds having hypolipidemic, hypocholesteremic activities process for their preparation and pharmaceutical compositions containing them and their use in medicine

  摘要：

  具有降脂和降胆固醇活性的新型β-芳基-α-取代丙酸。

  公开号：

  US20030236254A1

文献信息

• Novel Pyrroles Having Hypolipidemic Hypocholesteremic Activities, Process for Their Preparation and Pharmaceutical Compositions Containing Them and Their Use in Medicine
  申请人：Lohray Bhushan Braj

  公开号：US20070238776A1

  公开（公告）日：2007-10-11

  The present invention relates to novel substituted pyrrole compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. This invention particularly relates to novel substituted pyrrole compounds of the general formula (I), their analogs, their derivatives, their polymorphs, their tautomeric forms, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and their pharmaceutical compositions containing them. The invention also relates to the process for preparing such compounds, a composition containing such a compound and the use of such a compound and composition in medicine. The compounds lower triglyceride levels in blood and may be useful in the treatment of obesity, hyperlipidaemia, hypercholesteremia, syndrome X and diabetes.

  本发明涉及新型取代吡咯化合物，其衍生物，类似物，互变异构体，立体异构体，多晶形态，其药学上可接受的盐，其药学上可接受的溶剂和含有它们的药学上可接受的组合物。本发明特别涉及一般式(I)的新型取代吡咯化合物，其类似物，衍生物，多晶形态，互变异构体，药学上可接受的盐，药学上可接受的溶剂和含有它们的药物组合物。本发明还涉及制备这种化合物的过程，含有这种化合物的组合物以及在医学中使用这种化合物和组合物。这些化合物可以降低血液中的三酰甘油水平，并可能在肥胖症，高脂血症，高胆固醇血症，X综合症和糖尿病的治疗中有用。
• Novel pyrroles having hypolipidemic hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them and their use in medicine
  申请人：Lohray Braj Bhushan

  公开号：US20110275669A1

  公开（公告）日：2011-11-10

  The present invention relates to compounds of the general formula (I) their derivatives, their analogs, their tautomeric forms, their pharmaceutically acceptable salts, wherein all variables are as defined in the specification.

  本发明涉及公式（I）的化合物及其衍生物、类似物、互变异构体、药学上可接受的盐，其中所有变量如规范中所定义。
• Pyrroles having hypolipidemic hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them and their use in medicine
  申请人：Cadila Healthcare Limited

  公开号：US08212057B2

  公开（公告）日：2012-07-03

  The present invention relates to novel substituted pyrrole compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. This invention particularly relates to novel substituted pyrrole compounds of the general formula (I), their analogs, their derivatives, their polymorphs, their tautomeric forms, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and their pharmaceutical compositions containing them. The invention also relates to the process for preparing such compounds, a composition containing such a compound and the use of such a compound and composition in medicine. The compounds lower triglyceride levels in blood and may be useful in the treatment of obesity, hyperlipidaemia, hypercholesteremia, syndrome X and diabetes.

  本发明涉及新的取代吡咯化合物、它们的衍生物、类似物、互变异构体、立体异构体、多晶型、药学上可接受的盐、药学上可接受的溶剂和含有它们的药学上可接受的组合物。本发明特别涉及一般式（I）的新的取代吡咯化合物、它们的类似物、衍生物、多晶型、互变异构体、药学上可接受的盐、药学上可接受的溶剂和含有它们的药物组合物。本发明还涉及制备这种化合物的过程、含有这种化合物的组合物以及在医药中使用这种化合物和组合物的用途。这些化合物可以降低血液中的甘油三酯水平，并可用于治疗肥胖症、高脂血症、高胆固醇血症、X综合症和糖尿病。
• Heterocyclic compounds having hypolipidemic, hypocholesteremic activities process for their preparation and pharmaceutical compositions containing them and their use in medicine
  申请人：Cadilla Healthcare Limited

  公开号：US07041837B2

  公开（公告）日：2006-05-09

  Novel β-aryl-α-substituted propanoic acids having hypolipidemic and hypocholesteremic activities.

  具有降脂和降胆固醇活性的新型β-芳基-α-取代丙酸。
• NOVEL PYRROLES HAVING HYPOLIPIDEMIC HYPOCHOLESTEREMIC ACTIVITIES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN MEDICINE
  申请人：CADILA HEALTHCARE LIMITED

  公开号：EP1414439B1

  公开（公告）日：2011-05-04